Regulatory News Item
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
FOR IMMEDIATE RELEASE
("Smiths" or the "Company")
ADJOURNMENT OF GENERAL MEETING DUE TO RECEIPT OF SUPERIOR PROPOSAL
The Company is pleased to announce that at the General Meeting held earlier today, the resolution seeking approval for the indefinite adjournment of the General Meeting (the "Adjournment Resolution") was duly approved by shareholders by way of a show of hands.
A copy of the Adjournment Resolution will be submitted to the National Storage Mechanism ("NSM") and will be available for inspection on the NSM's website at National Storage Mechanism |
Details of the result of the vote by way of show of hands and a copy of the Adjournment Resolution will also shortly be made available on the Company's website at www.smiths.com/proposed-sale-of-smiths-medical.
The Company will provide further information regarding the ICU Transaction and the actions required of shareholders in respect of it as soon as reasonably practicable.
+44 (0)20 7004 1600
Jemma Spalton, Director of Investor Relations
+44 (0)20 3727 1340
Alex Le May /
Goldman Sachs (Joint Sponsor, Joint Financial Adviser & Joint Corporate Broker)
+44 (0)20 7774 1000
JP Morgan Cazenove (Joint Sponsor, Joint Financial Adviser & Joint Corporate Broker)
+44 (0)20 7742 4000
Gleacher Shacklock (Joint Financial Adviser)
+44 (0)20 7484 1150
Smiths is a global technology company listed on the
This announcement is not intended to, and does not constitute or form part of, any offer or invitation to purchase, acquire, subscribe for, sell, dispose of or issue, or any solicitation of any offer to sell, dispose of, purchase, acquire or subscribe for, any security or a solicitation of any vote or approval, in any jurisdiction. Smiths' shareholders are advised to read carefully the formal documentation in relation to the ICU Transaction once it has been despatched. Any response to the ICU Transaction should be made only on the basis of the information in the formal documentation to follow.
The release, publication or distribution of this announcement in jurisdictions other than the United Kingdom may be restricted by law and, therefore, any persons who are subject to the laws of any jurisdiction other than the United Kingdom should inform themselves about, and observe, any applicable requirements. Any failure to comply with these requirements or restrictions may constitute a violation of the securities laws or regulations of any such jurisdiction. This announcement has been prepared for the purposes of complying with English law and the UK Listing Rules and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of any jurisdiction outside of England.
Important information relating to the joint financial advisers and joint sponsors
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the